Description
Description
Simulect 20mg injection is a monoclonal antibody with an active ingredient called Basiliximab. It belongs to the medication class known as immunosuppressant. It is used to prevent the rejection of kidney transplants. It is injected within the first 4 to 6 weeks following the transplant. It is used on adults, adolescents, and children. When a transplanted organ is introduced, the body’s immune system recognizes it as foreign and attempts to reject it. This medicine works by inhibiting the immune cells responsible for attacking the transplanted organs. After treatment, your doctor may prescribe medicine (Ciclosporin and Corticosteroids) to protect the new kidney.
Do not consume Simulect 20mg injection medicine if you are allergic to Basiliximab and its other ingredients and if you are pregnant or breastfeeding. Before starting the treatment, inform your doctor if you had a transplant in the past and failed after a brief period or if you have ever been in the operating room for an unsuccessful transplant. Do not take any vaccine without consulting your doctor. Inform your physician if you are pregnant or planning to get pregnant. Use effective contraception to avoid pregnancy while undergoing therapy and up to 4 months after the last dosage. Do not breastfeed for up to four months after the second dose. Discuss more fertility concerns with your doctor.
Date of Approval
The U.S. FDA-approved Basiliximab to prevent the rejection of kidney transplants on May 12, 1998. Basiliximab injection is an immunosuppressant with an active ingredient called Basiliximab. It belongs to the medication class known as monoclonal antibody.
Mechanism of Action of BASILIXIMAB
Basiliximab is a monoclonal antibody. It targets and inhibits the activation of an interleukin-2 receptor alpha (IL-2Rα) receptor. This action will reduce the activation and proliferation of immune cells, particularly T lymphocytes (T cells), which are involved in organ rejection.
Uses of BASILIXIMAB
